XML 14 R4.htm IDEA: XBRL DOCUMENT v3.22.2
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Income Statement [Abstract]        
Revenue $ 43,660 $ 38,505 $ 82,280 $ 76,947
Operating expenses        
Cost of revenue 13,221 10,765 26,413 20,756
Research and development 37,037 37,800 74,876 71,572
Sales and marketing 24,281 23,216 50,374 43,820
General and administrative 21,200 16,066 45,344 31,002
Amortization of intangible assets 423 423 842 842
Total operating expenses 96,162 88,270 197,849 167,992
Loss from operations (52,502) (49,765) (115,569) (91,045)
Interest and other income, net 418 464 689 1,102
Net loss (52,084) (49,301) (114,880) (89,943)
Add: Net loss attributable to noncontrolling interest 38   98  
Net loss attributable to Adaptive Biotechnologies Corporation $ (52,046) $ (49,301) $ (114,782) $ (89,943)
Net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic $ (0.37) $ (0.35) $ (0.81) $ (0.64)
Weighted-average shares used in computing net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic 142,363,589 140,359,317 142,032,261 139,667,380
Net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, diluted $ (0.37) $ (0.35) $ (0.81) $ (0.64)
Weighted-average shares used in computing net loss per share attributable to Adaptive Biotechnologies Corporation common shareholders, diluted 142,363,589 140,359,317 142,032,261 139,667,380